10-KPeriod: FY2016

DEXCOM INC Annual Report, Year Ended Dec 31, 2016

Filed February 28, 2017For Securities:DXCM

Summary

DexCom, Inc. (DXCM) is a medical device company specializing in continuous glucose monitoring (CGM) systems for individuals with diabetes. As of the February 28, 2017, 10-K filing, the company's primary products are the G4 PLATINUM and G5 Mobile CGM systems. The G5 Mobile system has achieved a significant milestone with a non-adjunctive indication from the FDA, allowing it to be used as a replacement for fingerstick testing for diabetes treatment decisions, though it still requires daily calibration. The company is focused on expanding its product offerings and market reach, including targeting Type 2 diabetes patients and exploring new applications. DexCom is also investing in research and development, including collaborations, to advance its technology platform and develop next-generation products. Despite a history of net losses, the company has seen significant revenue growth and is building out its sales and marketing infrastructure. Key strategic priorities include driving product adoption, seeking broad reimbursement coverage, expanding target demographics, and enhancing its cloud-based data platform. The company faces intense competition but aims to maintain its technological leadership.

Financial Highlights

52 data points
Beta

Revenue

$573.30M

66.0% Gross Margin

Net Income

-$65.60M

-11.4% Net Margin

EPS (Diluted)

$-0.20

Total Assets

$402.80M

Cash & Equivalents

$94.50M

Free Cash Flow

$500K

Financial Statements
Beta
Revenue$573.30M
Cost of Revenue$194.90M
Gross Profit$378.40M
R&D Expenses$156.10M
SG&A Expenses$286.20M
Operating Expenses$442.30M
Operating Income-$63.90M
Interest Expense$700K
Net Income-$65.60M
EPS (Basic)$-0.20
Shares Outstanding (Basic)334.40M

Key Highlights

  • 1DexCom's G5 Mobile system is the first and only CGM system in the U.S. with a non-adjunctive indication, allowing it to replace fingerstick testing for treatment decisions.
  • 2The company is expanding its target market beyond Type 1 diabetes to include Type 2 diabetes patients, pre-diabetes individuals, and those who are obese.
  • 3Significant investment in R&D and strategic collaborations, including a notable partnership with Verily (formerly Google Life Sciences), are underway to develop next-generation CGM products.
  • 4DexCom is building a direct sales force and pursuing partnerships to drive adoption of its CGM systems.
  • 5Reimbursement from Medicare and private payors is a critical focus, with recent progress made in classifying Therapeutic CGMs as durable medical equipment under Medicare Part B.
  • 6The company is investing in manufacturing capacity expansion, including a new facility in Mesa, Arizona, to meet anticipated demand.
  • 7Despite a history of net losses, DexCom reported substantial revenue growth, driven by increasing sales of its disposable sensors and durable systems.

Frequently Asked Questions

DexCom's main products are the G4 PLATINUM and G5 Mobile Continuous Glucose Monitoring (CGM) systems. The G5 Mobile system is notable for having FDA approval for a non-adjunctive indication, meaning it can be used for diabetes treatment decisions without requiring frequent confirmatory fingerstick tests, though daily calibration is still necessary. The G5 Mobile also integrates with smartphones for data sharing via the DexCom Share System.

DexCom's strategy is to become the leading provider of CGM systems. Their current target market includes people with Type 1 diabetes using insulin pumps or multiple daily injections. They are actively expanding to target people with Type 2 diabetes on multiple daily injections and plan to broaden their reach to individuals with pre-diabetes and obesity in the future. This expansion is supported by a direct sales force and distribution agreements.

Key challenges include a history of net losses, intense competition from large medical device manufacturers, the lengthy and uncertain regulatory approval process (especially for new indications or products), dependence on third-party reimbursement from payors, the need for significant ongoing investment in R&D and manufacturing capacity, and potential supply chain disruptions from key component suppliers. The company also notes the inherent risks associated with medical device technology, including product liability and intellectual property disputes.

Reimbursement is a critical factor for adoption. As of February 2017, DexCom noted that CMS established a classification for 'Therapeutic Continuous Glucose Monitors' under Medicare Part B, which was enabled by the G5 Mobile's non-adjunctive indication. This is a significant step towards broader Medicare coverage. The company has also negotiated contracted rates with the seven largest private third-party payors, though coverage policies can be restrictive and require documentation of medical necessity.